GLP-1 drugs at longevity clinics

A narrative review published on 3 August 2026 in the Journal of Clinical Medicine takes up a question that longevity and aesthetic clinics have been answering commercially for years: whether anti-obesity medicines reach ageing biology and appearance^[1]. The review searched six databases and trial registries covering January 2010 to June 2026^[1]. Its conclusion is careful, and the care is the point. Semaglutide and tirzepatide do a great deal. Slowing human ageing is not yet among the things anyone has shown.

Licensed for disease, prescribed for ageing

The US label for Wegovy, the semaglutide brand for weight, lists three indications, each in combination with a reduced calorie diet and more physical activity. It covers reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It covers weight reduction and long-term maintenance in adults and children aged 12 and over with obesity, or adults with overweight plus at least one weight-related condition. And it covers noncirrhotic MASH with stage F2 to F3 liver fibrosis in adults^[2].

Zepbound, the tirzepatide brand for weight, is narrower. It covers weight reduction and maintenance in adults with obesity, or with overweight plus a weight-related condition, and moderate to severe obstructive sleep apnoea in adults with obesity^[3]. Both labels carry the same boxed warning about the risk of thyroid C-cell tumours^[2][3].

Every one of those indications names a disease and a body-weight threshold. None of them names ageing, skin quality, facial appearance or healthspan. A prescription written for one of those reasons is off-label.

What off-label prescribing does and does not mean

Off-label means a prescriber is using an approved medicine outside its approved indication. In the United States and the United Kingdom this is legal for a licensed prescriber and is ordinary across medicine. The manufacturer may not advertise the unapproved use, and the label gives the prescriber no guidance for it. What shifts is where the responsibility sits. A regulator has reviewed the evidence for the indication printed on the box, and for nothing beyond it.

That matters more than usual here, because the reason to prescribe in a longevity setting is often the absence of disease. Someone with a BMI of 24 and no cardiometabolic diagnosis sits outside every criterion on the semaglutide and tirzepatide weight labels^[2][3].

The longevity case, and where it thins out

The review reports that these drugs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations^[1]. The word "selected" is doing heavy lifting. Look at SELECT, the trial behind the cardiovascular result. It enrolled 17,604 people aged 45 or over who already had cardiovascular disease and a BMI of 27 or higher, and who did not have diabetes^[4]. Weekly semaglutide at 2.4 mg cut the primary composite endpoint from 8.0% to 6.5% over a mean 39.8 months, a hazard ratio of 0.80 (95% CI 0.72 to 0.90)^[4].

A real benefit, in people who were already ill. The same trial recorded adverse events leading to permanent discontinuation in 16.6% of the semaglutide group against 8.2% on placebo^[4]. Nothing in that dataset speaks to a healthy 45-year-old taking the drug in order to age more slowly.

On ageing biology proper, the review is blunt. Exploratory proteomic and epigenetic analyses suggest effects partly independent of weight loss, but the review states plainly that these do not establish slowed ageing^[1]. That is the honest version of the sentence a clinic brochure turns into "reverses your biological age".

The appearance changes are a side effect, not an indication

Rapid, large-magnitude weight loss drives the soft-tissue changes people call "Ozempic face" and "Ozempic body", alongside accelerated skin laxity and loss of lean mass, according to the review^[1]. It adds a qualifier worth keeping: the proportion of weight lost as lean tissue looks comparable to established agents^[1].

Lean mass is where the longevity framing runs into itself. A 2026 review in Trends in Endocrinology and Metabolism argues that expanding use of these drugs in older adults raises an overlooked question about whether cardiovascular and renal protection can come at the expense of muscle mass, nutritional resilience and independence. Its authors propose a geriatric-informed prescribing framework that redefines treatment success beyond weight loss^[6]. A clinic optimising for a scale reading is not optimising for that.

The drugs the field is most excited about are not licensed

Newer multi-receptor agents act with greater metabolic specificity, the review notes. Glucagon-containing agents such as survodutide and the triple agonist retatrutide preferentially reduce visceral and hepatic fat, with liver-fat reductions of roughly 60% to 80% in places^[1]. The review calls that a quality of weight loss arguably more relevant to healthspan than its quantity^[1].

Retatrutide is not approved by any regulator. Its Phase 3 obesity trial, TRIUMPH-1, enrolled 2,335 participants and reached primary completion on 6 April 2026. Entry required a BMI of 30 or above, or 27 with hypertension, dyslipidaemia, sleep apnoea or cardiovascular disease, and people with diabetes were excluded^[5]. Anything sold as retatrutide outside a trial did not come through a regulated supply chain.

What none of this evidence covers

No trial has randomised metabolically healthy adults to a GLP-1 drug and followed them for ageing outcomes. The endpoints behind both weight labels were body weight, glycaemic control, cardiovascular events and sleep apnoea severity^[2][3][4]. Lifespan has never been one. Neither has skin quality: the review's aesthetic material describes phenomena reported in patients rather than outcomes measured against a comparator^[1].

One more limit sits on the review itself. It is a single-author narrative review rather than a systematic review with pooled estimates, so it maps the field rather than weighing it^[1]. Useful for orientation. Thin as a basis for a prescription.

If a clinic offers you semaglutide or tirzepatide for longevity or appearance rather than for a diagnosed condition, the fair questions are which licensed indication you actually meet, what the prescriber expects the drug to do that the label does not claim, and how lean mass will be watched over time. Our regulatory notes set out country-by-country status.

This article is educational and is not medical advice. Whether one of these medicines is appropriate for you, and for what reason, is a decision for a qualified healthcare provider who knows your history.